IBI38D9-L

N/A

Report date: 2026/03/19 17:16:39

Base Information

Drug NameIBI38D9-L
Drug Alias NameIBI38D9-L
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD79BAnti-CD3
TargetsB-cell antigen receptor complex-associated protein beta chainT cell surface glycoprotein CD3
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A